[ad_1]
EnglishAstraZeneca is likely to conduct additional trials around the world to test the efficacy of the new Coronavirus Infectious Diseases (COVID19) vaccine, which was developed jointly with the University of Oxford. Pascal Sorio, CEO, said. The tentative analysis of the company’s vaccine raises questions about its efficacy.
The new trial will be conducted separately from ongoing trials in the United States. We will investigate the effect of low-dose administration, which showed greater efficacy than single-dose administration in a preliminary analysis. AstraZeneca released the results of a trial in which half the dose was administered, but admitted that this administration It was due to an error in the manufacturing process, and added to the test results.Questions arise. A new test will be carried out to see if the higher 90% efficiency is maintained.
“We have to test the results that show relatively high efficacy, so additional tests are needed,” Sorio said in his first interview after the announcement of the preliminary analysis. The additional trial was another “international trial, but it won’t take long. It turns out to be very effective, so we don’t need as many subjects,” he continued.
It also acknowledged that the additional tests are not expected to delay approval by the UK and European Union (EU) authorities. The US Food and Drug Administration (FDA) is unlikely to issue a vaccine based on the results of tests conducted in other countries, and given the questionable results, it may take a relatively long time to obtain permission. Said the CEO of Sorio. Permits from some countries are expected to still be obtained by the end of the year.
AstraZeneca and the University of Oxford announced on day 23 that the efficacy was 90% in a relatively small group of subjects who received half the dose in the first dose and the full dose in the second dose. On the other hand, it was 62% in the group that was the total amount both times.
Astra Zeneca, possibility of additional tests
Markets: European closure ”. (Source: Bloomberg)
Original title:Astra likely to conduct additional global vaccine trial, says CEO (3) （抜 粋）
(The purpose of the exam will be added and updated after the second paragraph.)
